Advertisement

Topics

Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500

19:23 EDT 28 Jul 2018 | BioPortfolio Reports

Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR Pipeline Review, H2 2018


Summary


Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor Pipeline Review, H2 2018, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR Glucosedependent insulinotropic polypeptide receptor GIPR is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic betacells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucosedependent insulinotropic polypeptide GIP also known as gastric inhibitory polypeptide.


Glucosedependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G proteincoupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.


The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, NonAlcoholic Steatohepatitis NASH and Parkinson's Disease.


Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR

The report reviews Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics and enlists all their major and minor projects

The report assesses Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Gastric Inhibitory Polypeptide Receptor Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...